In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (D13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence in situ hybridization (iFISH) in a large multicenter study (n ¼ 794). The ability to obtain abnormal metaphases was associated with a poor prognosis, which was worse if D13, p53 deletion or t(4;14) was present, but only D13 remained significant on multivariate analysis. Patients with D13, by either cytogenetics or iFISH, had a poor prognosis. However, when cases with D13 detectable by both cytogenetics and iFISH were separated from those detected by iFISH only, the poor prognosis of iFISH-detectable D13 disappeared; their outcome matched that of patients with no detectable D13 (P ¼ 0.115). Addition of ploidy status to iFISH-D13 did not affect the prognostic value of the test. Indeed both cytogenetics and iFISH D13 divided both hyperdiploidy and nonhyperdiploidy into two groups with similar prognoses, indicating that the poor prognosis of ploidy is entirely due to its association with D13. We conclude that D13 detected by metaphase analysis is a critical prognostic factor in myeloma. Absence of D13, even in those patients yielding only normal or no metaphases, is associated with a relatively good prognosis.
Introduction
Recurrent cytogenetic features can be used to identify two different pathogenic pathways leading to myeloma. The first of these comprises nonhyperdiploid (non-HRD) tumours with a high incidence of immunoglobulin heavy chain translocations (IgHt), involving five defined chromosomal partners. The second group comprises HRD tumours associated with multiple nonrandom trisomies with a low incidence of IgHt. The five defined translocation partners involve the chromosomal loci 4p16 (deregulation of FGFR3 and MMSET), 11q13 and 6p21 (overexpression of cyclin D1 and D3, respectively), 16q23 (c-MAF) and 20q11 (MAFB). [1] [2] [3] [4] [5] The distribution of these IgHt is nonrandom being seen in approximately 70% of the non-HRD group but in less than 20% of the HRD group.
D13 is a recurrent chromosomal abnormality that has been associated with a high risk of early treatment failure and short survival. [6] [7] [8] [9] [10] [11] Using metaphase analysis, D13 (predominantly monosomy, but sometimes interstitial deletion 12 ) is present in B50% of patients with abnormal karyotypes. Since this method frequently fails to detect the abnormal clone, D13 is seen in only 10-20% of patients overall compared to the 40-50% usually seen by interphase fluorescence in situ hybridization (iFISH) analysis. 13 There has been controversy between centers relating to the impact of D13 on prognosis dependent on whether cytogenetics or iFISH is used. 6, 10, 11, 14 It is claimed that D13 detected by cytogenetics has a much worse outcome than D13 seen by iFISH only. This conclusion has been drawn from comparison of different publications as few studies, with variable results, have directly compared conventional cytogenetic and iFISH data from the same patients. [15] [16] [17] In this study, we have examined the effect of D13 on prognosis by both cytogenetics and iFISH in a large cohort of patients from different UK centers and compared the prognostic significance according to the detection method used.
Patients and methods

Patients
From October 2000 to July 2004, bone marrow (BM) samples from 794 patients from 95 different UK hospitals were received by the Leukaemia Research Fund UK Myeloma Forum Cytogenetic Database laboratory with informed consent for cytogenetic/FISH analysis: 195 of the patients from this series have been previously described. 18 The median age was 65 years (range 27-93 years) with 33% of patients over the age of 70 years and 19% over 75 years. The majority (78%) were studied at diagnosis, while 3% had a known previous history of monoclonal gammopathy of undetermined significance (MGUS). The diagnosis of myeloma was made according to the criteria of Durie et al. 19 Since most of the patients were nontrial there were significant difficulties with information retrieval. Analysis was therefore restricted to overall survival (OS), calculated from the time of sampling to the end of July 2005. Only the FISH results for D13 and the presence of any (unidentified) IgH rearrangement were reported to the referring clinician, with a statement to indicate that there was insufficient prognostic information to use these results in treatment decisions. We have no knowledge of changes to management on the basis of the results, although there is a possibility that this could have resulted in minor bias. Maximum follow-up was 56 months, with a median of 22 months. Seven patients were lost to follow-up.
Conventional cytogenetic studies
Cytogenetic studies were performed after density gradient separation of BM samples (lymphoprep, Axis-Sheild PoCAS, Oslo, Norway) and plasma cell (PC) percentage assessment on MGG-stained slides from cytospin preparations. Cells were cultured at 1 Â 10 6 ml À1 in RPMI 1640 supplemented with 20% fetal calf serum and 1 ng ml À1 IL-6 for 24 h (if 430% PC), 3 days and/or 6 days, depending on the quantity available. G-banded chromosomal analysis was carried out on 1-200 metaphases (median 25) depending on availability. Standard criteria to define a clone were applied, but 30 cases (13% of abnormal, 5% of total) had only one abnormal metaphase with typical myeloma abnormalities. These were considered as proof of a dividing clone when supported by iFISH and therefore were included in the analysis. Cryptic abnormalities (all t(4;14), some IgHt and deletion of p53 (dp53)) detected by iFISH were included in the abnormal karyotypes. Where possible, metaphase FISH confirmed that the iFISH abnormalities were present in the same cells as the abnormalities detected by conventional cytogenetics.
D13 was defined as visible loss of all or part of one chromosome 13 in a near diploid karyotype or loss of one or two copies of 13 in a near tetraploid karyotype. Three cases with 460 chromosomes and two copies of 13 were also classified as D13.
iFISH studies iFISH analysis was performed on purified PC from 729 patients (median PC percentage achieved 95%, range 30-100%) using the micro-FISH technique previously described. 18 Cutoff levels were 20% for numerical abnormalities and 10% for translocations, as defined by the European Myeloma Network-sponsored FISH in Myeloma Workshop (manuscript in preparation). Probes used were those previously published, 18 to which were added LSI D5S23/D5S721, CEP 9, CEP 15 and IgH-cMAF fusion probes (Abbott Diagnostics, Maidenhead, UK) as well as laboratory grown probes obtained from the Sanger Institute (Hinxton, UK) for CCND3 break-apart (RP11-298J23, RP5-973N23, RP11-533O20, RP11-7K24) and MAFB break-apart (RP11-79G10, RP11-264H10, RP5-1123D4, RP1-54G6, RP4-600E6). New patients were not tested with the centromeric probes for chromosomes 6 and 10, while testing for t(4;14) and t(14;16) in these patients was carried out with recently developed commercial probes (Abbott Diagnostics, Maidenhead, UK). Results were available for D13, IgHt, t(4;14) and t(11;14) on all 729 patients; for dp53 on 715, and ploidy status on 724 (196 as previously described 18 and the remainder using the 5/9/15 probe combination as detailed below). Although only partial analysis was possible, results were also available for t(6;14) (n ¼ 363), t(14;16) (n ¼ 335) and t(14;20) (n ¼ 53). D13 was defined as loss of signal for one or both 13q14 probes, except in cases classified as near tetraploid, in which loss of two copies of either/both probes was defined as D13.
Ploidy classification by iFISH
Ploidy was assessed using a modification of the method of Wuilleme et al. 20 All patients with an extra copy of probes for any two of chromosomes 5, 9 or 15 were defined as HRD. Cases not meeting these criteria but only showing loss of signals were defined as non-HRD, along with those having X4 copies of X4 probes (near tetraploidy, considered with non-HRD class 21 ). All other cases had their full iFISH result compared with the hypothetical result that would have been obtained for the same probes on all complete myeloma karyotypes in the Mitelman Database of Chromosomes in Cancer (689) (http://cgap.nci. nih.gov/Chromosomes/Mitelman). If 475% comparable cases were HRD or non-HRD then the appropriate category was assigned. No ploidy assignment was made if there were few comparable cases or they were equally divided between HRD and non-HRD. Only 5/729 (0.07%) could not be assigned and were excluded from the analysis. Comparison with actual karyotypes in the 199 patients with both results showed only one case where the assignment was incorrect (HRD in a non-HRD case) and this was changed for the analysis. This gives a sensitivity and specificity of approximately 99%, allowing for cases that could not be assigned.
Statistics
Comparisons of frequencies were carried out using exact inference methods (StatXact v 5, Cytel Software Corp., Cambridge, MA, USA), Kaplan-Meier survival plots and accompanying log-rank tests using MINITAB v14 (MINITAB Inc., PA, USA) and Cox proportional hazard regression using the specialist regression package EGRET v 2.0 (Cytel Software Corp.).
Results
Conventional cytogenetics
Metaphase analyses were carried out on 555 patients. The majority of these were patients with adequate sample for both cytogenetics and iFISH (n ¼ 490); 65 samples had conventional cytogenetics only. A total of 213/603 (38%) samples displayed numerical and structural abnormalities typical of myeloma. The frequencies of individual abnormalities are shown in Table 1 . Although generally the abnormality detection rate increased with increasing PC content of the samples ( Figure 1 ) a significant abnormality rate was found even in samples with o1% PC (15%). The non-HRD group (o47 or 475 chromosomes) comprised 84 cases (15% total, 39% abnormal), including 58 cases (10% total, 27% abnormal) with hypodiploidy or near tetraploidy (475 chromosomes). The non-HRD group showed a higher frequency of D13, (61/84, 73%) and of IgHt (66/75, 88%) than the HRD group (D13 42/129, 33%, IgHt 36/120, 30%) (Po0.001 for both). All 28 t(4;14) cases, 6/7 (86%) t(14;16) and all eight t(14;20) cases had D13. There were 28 cases with apparent loss of chromosome 17 or its short arm; these were less biased in their association with D13 (17/28, 61%) or non-HRD (16/29, 59%).
iFISH iFISH was carried out on 729 patients of whom 698/729 (96%) were abnormal for at least one of the tested abnormalities ( Table 1) . The frequencies and associations between the abnormalities detected by iFISH were similar to the same abnormalities as detected by cytogenetics (Table 2 ). There was a significant difference in incidence of specific IgHt abnormalities with age: 80/488 (16%) of patients p70 years old had a t (11;14) while 66/488 (14%) had a t(4;14) compared to 26/241 (10.8%) (P ¼ 0.04) and 19/241 (7.9%) (P ¼ 0.03) respectively in the 470 years age group.
Comparison of metaphase analysis and iFISH
All D13 seen by cytogenetic analysis were confirmed by iFISH and vice versa in cases with an abnormal karyotype, indicating that cryptic deletions of chromosome 13 are rare. Five patients had dp53 by FISH that was cryptic at the cytogenetic level, Importance of cytogenetic deletion 13 in myeloma L Chiecchio et al while one patient with a cytogenetic deletion of 17p retained both p53 signals. As well as known cryptic rearrangements of 14q32 (FGFR3/IgH, cMYC/IgH), cytogenetically visible rearrangements of 14q32 were observed that did not involve the IgH locus. A number of other apparent inconsistencies between cytogenetics and iFISH were resolved by metaphase FISH, which supported the iFISH results in all cases. These discrepancies largely resulted from misinterpretation of complex karyotypes.
Univariate analysis
In the group of patients studied by metaphase cytogenetics, univariate analysis showed the presence of an abnormal karyotype (P ¼ 0.001), the detection of abnormal metaphases only (Po0.001) and the presence of any specific abnormality, except t (11;14) , to be associated with shorter OS (Table 3 ). The t(11;14) was the only marker examined with a suggestion of better survival than for patients without the abnormality, but this was not significant (P ¼ 0.79). Non-HRD karyotypes appeared to be a stronger indicator of poor prognosis than hypodiploidy (P ¼ 0.003 vs P ¼ 0.064), although both showed the same median survival (MS) of 21 months. Non-HRD was therefore considered to be an acceptable measure of ploidy for the iFISH group. In the iFISH groups (Table 3) , all abnormalities tested, except t (11;14) , were associated with a shorter OS.
The impact of method of detection on clinical outcome Chromosome 13. The method used for the detection of D13 and the impact on survival is shown in Figure 2 . The survival difference between the presence or absence of chromosomal Table 1 Frequency of abnormalities detected in metaphases and by iFISH Importance of cytogenetic deletion 13 in myeloma L Chiecchio et al abnormalities detected by metaphase cytogenetics is shown in Figure 2a . In the absence of D13, patients with other chromosomal abnormalities showed no difference in survival from those in which no abnormalities were detected (Figure 2b ). For patients with iFISH D13 (Figure 2c ), the OS was worse than for patients lacking the abnormality (MS 24 months vs not reached), but was substantially better than for patients with metaphase-detectable D13 (MS 24 vs 15 months). The iFISH D13 cases which also had abnormal metaphases were separated from those where the D13 was only detectable by iFISH (Figure 2d ), which showed that the poor prognostic effect was confined to the former group. The latter group showed no significant difference in outcome from cases lacking D13 (P ¼ 0.115).
We examined whether the percentage of D13 positive cells detected by iFISH affected outcome. Patient groups with 21-50% (n ¼ 17), 51-80% (n ¼ 57) and 480% positive cells (n ¼ 274) were examined. Those patients with 480% D13 had a shorter OS than those with 21-50%, 51-80% or no evidence of D13 (27 vs 43 months, not reached and 47 months, Importance of cytogenetic deletion 13 in myeloma L Chiecchio et al respectively), but these results were similar to the survival of all patients with 420% D13 (29 months).
Ploidy. We used iFISH-detectable non-HRD to stratify patients on the basis of ploidy (see above) and investigated whether the distribution of D13 between the two aetiological groups defined by ploidy was contributing to the lesser effect of D13 on survival by iFISH detection. Using a combination of D13 and ploidy in both metaphase and iFISH analyses (Figure 3a and b) we have shown that knowledge of ploidy status adds nothing to the prognostic information derived by detecting D13. Conversely, the presence of D13 was able to divide both HRD and non-HRD patients into two groups, with the D13 groups having similar poor prognoses (Pp0.001) (Figure 3c and d) .
IgH translocations and p53. The poor prognosis of t(4;14), like that of D13, was shown to be dependent on the ability to obtain abnormal metaphases. There was no significant difference in survival between patients with a t(4;14) detectable only by iFISH and patients with no t(4;14) (P ¼ 0.353) (Figure 4a ). The worse outcome of those patients with t(4;14) and abnormal metaphases (P ¼ 0.019) was not a reflection of different frequencies of D13 in the two groups, since 97% of patients in both groups had D13. An analysis of patients with dp53 by presence or absence of visible chromosomal abnormalities (Figure 4b ) showed a similar trend but this did not reach significance (P ¼ 0.083).
We examined the effect of other poor prognostic markers (dp53, and poor prognosis IgHt) on survival of D13 patients ( Figure 5 ). The IgHt included t(4;14), t(14;16), t (14;20) and unidentified translocations within a non-HRD karyotype. Combined survival analysis of these abnormalities with D13
by iFISH identified a small number of patients (14/729, 2%) with a poor OS (13 months) similar to those patients with D13 seen by cytogenetics.
Multivariate analysis
Cox regression analysis of all cytogenetically detected markers showed only D13 to be a significant indicator of poor prognosis (P ¼ 0.002, hazard ratio 2.19). Similar analysis of all the iFISH abnormalities identified both D13 (P ¼ 0.046, HR 1.32) and dp53 (P ¼ 0.01, HR 1.644) as independent indicators of a poor prognosis. When age was added to the models the same genetic markers were significant, but with improved P values and hazard ratios (CCD13 Po0.001, HR 2.29, iFISH D13 P ¼ 0.041, HR 1.33, iFISH dp53 P ¼ 0.002 HR 1.82, age Po0.001 HR ¼ 1.03). Addition of D13 by conventional cytogenetics to the iFISH markers for the 490 patients with both types of testing showed that only D13 by conventional cytogenetics was an independent prognostic indicator (Po0.001 with or without age in the model, hazard ratio 2.15-2.25).
Discussion
We have performed a direct comparison of iFISH and conventional cytogenetics in myeloma, and used the results of the metaphase analysis to validate iFISH results. We have examined the effect of the PC percentage in the cytogenetic sample for the likelihood of obtaining abnormal metaphases. The observation that some of the samples with very high PC percentages failed to yield abnormal karyotypes confirmed that the ability of myeloma cells to divide in vitro is a fundamental biological property of the disease. Importance of cytogenetic deletion 13 in myeloma L Chiecchio et al
Despite the large scale and multicenter approach to this study, we obtained the same results for the relative effect of D13 seen by conventional cytogenetics and iFISH as series in which all samples originated from a single center. 16, 17 The presence of D13 was associated with an adverse prognosis when studied by either metaphase analysis or iFISH, on both univariate (Po0.001 for both) and multivariate (P ¼ 0.002, cytogenetics; P ¼ 0.046, iFISH) analysis. However, although detected in considerably fewer patients (18% by cytogenetics vs 47% by iFISH), D13 detected in metaphases imparted a significantly shorter OS than D13 by iFISH (MS 15 vs 29 months). This was shown to be due to the iFISH group being composed of a mixture of cases from the cytogenetically detected D13 group with a grave prognosis and other patients with essentially the same prognosis as those with no D13.
It has been suggested that applying a high cutoff value for iFISH D13 may bring the iFISH results more in line with the cytogenetics results. This was not so in our patients: raising the cutoff level to 80% only reduced the MS by 2 months with no additive effect for any other analysis. An attempt has been made to distinguish the poorest prognosis D13 patients detected by iFISH by combining D13 with the PC labelling index; 16 that too was unsuccessful. In this study, we investigated whether the addition of ploidy status could usefully stratify those patients with D13 detected by iFISH. Hypodiploidy has been strongly associated with a poor prognosis in myeloma from both cytogenetic and DNA index studies. [21] [22] [23] [24] The strong correlation between D13 and non-HRD 5 was confirmed in our study. Previous reports have provided conflicting information on the relative importance of D13 and ploidy in relation to prognosis. 21, 22 One group reported that D13 was simply a surrogate marker for hypodiploidy and another that both were independent markers of an extremely poor prognosis. Univariate and multivariate analysis showed that, in our series, non-HRD status added nothing to the prognostic information obtained from D13. This was true for both iFISH and metaphase analysis, with hypodiploidy also having no additive effect on D13 in the latter.
Deletion of p53 was an independent prognostic indicator for the total group of patients with iFISH results (P ¼ 0.01), with survival approaching that of D13 detected by cytogenetics (19 vs 15 months). However, the small number of patients with dp53 at diagnosis (7% in this series) makes it a less useful prognostic marker. The 12% of patients with a t(4;14) had a similar survival to those with dp53, but this marker did not reach significance in any of the multivariate analyses. Combining results from all poor risk abnormalities detected by iFISH identified a group of patients with a similar poor outcome to that seen for D13 detected in metaphases, but only 2% of patients were in this category.
The overall metaphase abnormality detection rate of 37% was in line with previous studies. 25 The detection of chromosomal changes in metaphases was associated with significantly reduced survival but, as reported by the Little Rock group, 10, 26 the tight association between the presence of abnormalities and poor outcome appeared to be almost entirely due to the strong impact of D13, present in 48% of the abnormal cases. The clinical course of patients with other, nonchromosome 13, abnormalities was not significantly different from that of patients who had normal or failed karyotypes by conventional cytogenetics.
The significant effect of a cytogenetically detectable abnormal karyotype on the prognosis of patients with t(4;14) was shown for the first time. This cryptic abnormality is only detectable by FISH, and in this patient group, those with detectably abnormal metaphases contributed entirely to the poor prognosis, while those with t(4;14) and a normal or failed karyotype showed a similar prognosis to patients without the translocation. As t(4;14) is strongly correlated with D13, it may be argued that this result was due to the effect of D13. Patients with dp53 also appeared to show a worse prognosis if the abnormal karyotype could be detected in culture but this did not reach statistical significance (P ¼ 0.083). This could be due to the much smaller number of patients or to the lower proportion of dp53 patients who also had a D13 (60%). More patients will need to be studied to resolve whether abnormalities other than D13 genuinely show a difference in prognosis dependent on their ability to divide in vitro. It has been suggested that this ability stems from the myeloma cells gaining independence from the BM stroma, and Importance of cytogenetic deletion 13 in myeloma L Chiecchio et al D13 patients with this ability have been shown to have a distinct expression profile. 16 We have previously shown that age has a significant effect on the impact of iFISH chromosome abnormalities in myeloma. 18 In this study, the addition of age to the multivariate models did not affect which genetic markers were significant, although it did strengthen the apparent effect of these markers. The relatively short follow up time (median 22 months) of this study may have an impact on the perceived importance of some abnormalities; in particular the t(4;14) may take longer to show a significant effect when detected by iFISH. Nevertheless, the clear impact on prognosis of the abnormalities detected in metaphases has indicated their much greater effect on the course of the disease. More than 20% of the samples in this study were from patients studied more than 6 months after diagnosis. Exclusion of these patients had little effect on the overall results, other than reducing the statistical power. Shaughnessy et al. 10 have previously shown that the acquisition of cytogenetically detectable abnormalities has a detrimental effect on prognosis from the time at which they are detected. As we cannot be certain which abnormalities were present from diagnosis, it is not valid to extrapolate back to the time of diagnosis.
This study has confirmed the unique importance of metaphase analysis in the determination of prognosis in myeloma. We have verified that the poor prognostic effect of D13 detected by iFISH is less than for metaphase detection. This means that D13 detected by iFISH is an inadequate independent prognostic indicator on which to base treatment choices. Combining patients with D13 detected by iFISH with the other known genetic prognostic indicators failed to identify sufficient patients with a grave prognosis to be used as a suitable alternative to conventional cytogenetic analysis. Although dp53 can also give prognostic information, the number of affected patients is so small that it is not clear that it can compete with cytogenetic detection of D13 for prognosis. Although adequate cytogenetic analysis of myeloma is demanding, we have shown that it is extremely effective, even in a multi-center setting. Metaphase analysis can be readily attempted by all routine cytogenetics laboratories, unlike myeloma iFISH which requires additional techniques or equipment compared to other haematological iFISH. The major emphasis of a diagnostic test should be in the detection of chromosome 13 abnormalities in dividing cells, although metaphase FISH for t(4;14) and dp53 may prove to add useful information. Although only a small proportion of the cases with abnormal karyotypes can be detected by cytogenetic analysis of BM from myeloma patients, it is now clear that deletion of chromosome 13 only provides useful information in the context of a visible chromosomal abnormality. Those patients with a normal or failed cytogenetic result have a much better prognosis, even if they can be shown by iFISH to harbour a deletion of chromosome 13.
